Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.24 +0.43 (+3.40%)

Streaming Delayed Price Updated: 3:57 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? ↗

March 08, 2026

This run could be short-lived.

Via The Motley Fool

Topics Death

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 03, 2026

The growth investor kicked off this week by buying up some hard-hit stocks.

Via The Motley Fool

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

Via FinancialNewsMedia

Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗

March 02, 2026

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Via Stocktwits

Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones ↗

February 26, 2026

Via Chartmill

Intellia (NTLA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Intellia (NTLA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? ↗

February 07, 2026

Will this biotech's innovative platform finally pay off?

Via The Motley Fool

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About? ↗

January 27, 2026

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total...

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today ↗

January 16, 2026

Via Stocktwits

Topics Stocks

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗

January 16, 2026

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Via Stocktwits

Topics Artificial Intelligence ETFs

Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares ↗

January 12, 2026

Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public filings.

Via The Motley Fool

Topics Regulatory Compliance

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗

December 29, 2025

Don't get too excited about their prospects.

Via The Motley Fool

Topics Death

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

Intellia (NTLA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Intellia (NTLA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

From MarketNewsUpdates.com

Via GlobeNewswire

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

Via FinancialNewsMedia

2 Beaten-Down Stocks to Avoid Right Now ↗

November 15, 2025

There might be plenty more downside for these biotechs.

Via The Motley Fool

Topics Death

This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday ↗

November 12, 2025

Via Benzinga

This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday ↗

November 11, 2025

Via Benzinga

What 21 Analyst Ratings Have To Say About Intellia Therapeutics ↗

November 11, 2025

Via Benzinga

Why Gene-Editing Giants Crispr And Intellia Just Surged ↗

November 10, 2025

The companies are working on one-and-done treatments for diseases tied to genetic problems.

Via Investor's Business Daily

Topics Death

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 07, 2025

Via Benzinga

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗

November 07, 2025

Wall Street may be overestimating these companies' potential.

Via The Motley Fool

Discover the top movers in Friday's pre-market session. ↗

November 07, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 07, 2025

Via Benzinga

Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

November 07, 2025

Via Benzinga

Intellia Therapeutics Inc (NASDAQ:NTLA) Plummets 24.5% After FDA Places Clinical Hold on Phase 3 Trials ↗

November 06, 2025

Intellia stock plunges after FDA places clinical hold on its Phase 3 trials for lead candidate nex-z, overshadowing Q3 earnings.

Via Chartmill

What's going on in today's after hours session ↗

November 06, 2025

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.